Related Experiment Video
Updated: May 23, 2026
09:03
Forward Genetic Approaches in Chlamydia trachomatis
Published on: October 23, 2013
Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection
Shanta Raj Bhattarai1, So Young Yoo, Seung-Wuk Lee
1Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Biomaterials
|April 13, 2012
Summary
Engineered M13 phage carrying Chlamydia trachomatis (Ct) peptides show potential as a novel microbicide. This phage-based material effectively reduced Ct infection in human cells, offering a new strategy against sexually transmitted infections.
Area of Science:
- Biotechnology
- Microbiology
- Materials Science
Background:
- Developing effective treatments against sexually transmitted pathogens like Chlamydia trachomatis (Ct) is challenging due to difficulties in material selection and achieving cellular permeability.
- Currently, no effective vaccines or microbicides exist for Ct, a globally prevalent pathogen.
Purpose of the Study:
- To engineer a novel phage-based material for potential therapeutic use against Chlamydia trachomatis (Ct) infection.
- To assess the efficacy of engineered M13 phage displaying Ct-specific peptides in reducing Ct infection in human cells.
Main Methods:
- Engineered the M13 bacteriophage to display two functional peptides: an integrin-binding peptide (RGD) and a segment of Ct's polymorphic membrane protein D (PmpD).
- Evaluated the intracellular trafficking and ability of engineered phage to reduce Ct infection in HeLa and primary endocervical cells.
- Used polyclonal antibodies against PmpD to investigate the role of PmpD in the observed anti-Ct activity.
Main Results:
- Engineered M13 phage successfully expressed both RGD motifs and Ct peptides, and demonstrated intracellular trafficking.
- Phage treatment significantly reduced Ct infection in both HeLa and primary endocervical cells compared to controls.
- Antibody neutralization experiments indicated that PmpD is the key component responsible for the observed reduction in Ct infection.
Conclusions:
- Engineered M13 phage displaying Ct-derived peptides can effectively reduce Chlamydia trachomatis infection in human cells.
- Phage-based vector delivery systems show promise in overcoming mucosal barriers for preventing sexually transmitted infections.
- This approach offers a potential new avenue for developing microbicides against challenging pathogens like Ct.
Related Concept Videos
01:29Bacterial Phylum Chlamydiae
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...
01:30Lytic Cycle of Bacteriophages
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
02:53CRISPR and crRNAs
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...